Exchange: NYSE·Updated 07:36 PM EDT

LLY News

News
all
press releases
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.read more...
Benzinga
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.read more...
Benzinga
More News
Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver SlidePR NewswireVANCOUVER, BC, Oct. 14, 2026Stock Preachers News CommentaryVANCOUVER, BC, Oct. 14, 2026 /PRNewswire...
PR Newswire
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
Zacks
Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.
Stocktwits
Bet on These Healthcare ETFs to Benefit From the Aging US Population
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.
Zacks
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026SAN DIEGO, Oct. 14, 2026 /PRNewswire...
PR Newswire
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsBristol Myers Squibb offers a significant yield and recovery in net income, supported by its strong oncology and cardiovascular segments...
Nasdaq News: Markets
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
Zacks
Notable Tuesday Option Activity: LLY, WULF, CNXN
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Eli Lilly (Symbol: LLY), where a total volume of 19,878 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0...
Nasdaq News: Markets
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Prelude expects patient enrollment to begin in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.
Stocktwits

Advertisement|Remove ads.